Fulton Bank, N.A. Argenx Se Transaction History

Fulton Bank, N.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 04, 2024	BUY	$338.91 - $506.01 $7,117 - $10,626	21 Added 3.9%	560 $213,000
Q3 2023 Oct 04, 2023	BUY	$369.35 - $548.43 $5,909 - $8,774	16 Added 3.06%	539 $264,000
Q2 2023 Jul 06, 2023	SELL	$360.14 - $422.58 $5,402 - $6,338	-15 Reduced 2.79%	523 $203,000
Q1 2023 Apr 06, 2023	BUY	$334.23 - $403.65 $2,339 - $2,825	7 Added 1.32%	538 $200,000
Q4 2022 Jan 05, 2023	BUY	$342.17 - $402.31 $181,692 - $213,626	531 New	531 $201,000
Q2 2022 Jul 07, 2022	BUY	$269.58 - $378.88 $147,999 - $208,005	549 New	549 $208,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Fulton Bank, N.A., based on Form 13F filings with the SEC.

Stay updated on Fulton Bank, N.A. with notifications on news.